研报掘金丨浙商证券：维持天士力“买入”评级，业绩符合预期，看好三九赋能

Core Viewpoint - Zhejiang Merchants Securities report indicates that Tianjin Tasly Pharmaceutical achieved a net profit attributable to shareholders of 984 million yuan in the first three quarters, representing a year-on-year increase of 16.88% [1] - In Q3 alone, the net profit attributable to shareholders was 210 million yuan, also reflecting a year-on-year growth of 16.56% [1] - The performance aligns with expectations, and there is optimism regarding the empowerment from Sanjiu [1] Financial Performance - The net profit for the first three quarters reached 984 million yuan, marking a 16.88% increase compared to the previous year [1] - The Q3 net profit was recorded at 210 million yuan, showing a 16.56% year-on-year growth [1]